A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

Phase 3 Completed 151 enrolled Arthritis Innovation Corporation Allucent · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.

Timeline

Start: 2022-11-17
Primary completion: 2023-11-22
Completion: 2024-08-23

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	625 mg	Other
Background	Acetaminophen	Small molecule	—	—
Background	Bupivacaine	Other / unclassified	0.25 %	—
Background	Methocarbamol	Small molecule	—	—

Indications

No indication recorded.